All Archives - TimmermanReport.com

Oct

2017

Gilead’s Thrilling CAR-T Victory, Celgene’s Agonizing Crohn’s Defeat, & Vir Goes Big

Luke Timmerman

All

20 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Oct

2017

Vir Biotechnology, a ‘Shock and Awe’ Startup, Bets on Infectious Disease with $500M+

Luke Timmerman

All, Vaccines

18 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Oct

2017

VC Briefs: Gemini’s $42M for Dry AMD & Mission Bio’s $10M for Single-Cell Analysis

Luke Timmerman

All, Venture Capital

17 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Oct

2017

Exclusive: Illumina Ventures Rakes in $230M Fund, Declares Independence from Parent, Mostly

Luke Timmerman

All, The Edge

16 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Oct

2017

Spark Gene Therapy Sails Thru AdComm, Broad Institute Nuzzles Up to Deerfield, Pfizer’s Cancer Deal in Africa

Luke Timmerman

All

13 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Oct

2017

George Yancopoulos on Threading the Price Needle, and Building a Biotech to Last

Luke Timmerman

All

11 Oct 2017

George Yancopoulos, the president and chief scientific officer, started his biotech career in 1989 at Regeneron Pharmaceuticals. He’s been there ever since, and has pretty much seen it all. It was a pleasure to have him as the guest for Episode 3 of The Long Run podcast. Yancopoulos, in this recording at Regeneron offices in Tarrytown, NY, talks about how...

Oct

2017

Where Does Alzheimer’s R&D Go Now? Plenty of Directions

Luke Timmerman

All, The Edge

09 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Oct

2017

IPO Market Finds a Rhythm, FDA Huddles with FTC on Pricing, & Praluent Gets to Stay

Luke Timmerman

All

06 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Oct

2017

Nimbus Rinses and Repeats, Enticing Celgene With Immunology Drug Candidates

Luke Timmerman

All, Venture Capital

03 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Oct

2017

KSQ Scores $76M, Lures Meeker to CRISPR Dream of ‘High Confidence Drug Development’

Luke Timmerman

All, Cancer, Venture Capital

02 Oct 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Sep

2017

The Long Run Ep. 2: Editas Medicine CEO Katrine Bosley

Luke Timmerman

All

27 Sep 2017

Katrine Bosley, the CEO of Cambridge, Mass.-based Editas Medicine, is the guest for Ep. 2 of “The Long Run” biotech podcast. Editas, an aspiring leader in the field of CRISPR-based genome editing, is still a very young company. It was founded in 2013 with a license to use technology from the Broad Institute of MIT and Harvard. Within two years,...

Sep

2017

Socializing After Hours: It’s How Biotech Runs, and Should Be Open to All

Luke Timmerman

All, The Edge

25 Sep 2017

Back in the “Mad Men” era, there was the three-martini lunch. When boozy mid-day breaks went out of style, business executives found other ways to grease the wheels of social interaction outside of the office. Like doing deals on the golf course. There are many ways to cultivate the social connections that are a crucial step toward forming trusting relationships...

Sep

2017

Alnylam Gets Over the Hump, Nabriva Nails Antibiotic Trial & Biosimilar Avastin Arrives

Luke Timmerman

All

22 Sep 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Sep

2017

After the Boom: How’s It Going for Big Pharma Vets At Startups?

Luke Timmerman

All, People, The Edge

18 Sep 2017

This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.

Sep

2017

The Long Run, Ep. 1: Conversation with Alnylam CEO John Maraganore

Luke Timmerman

All

13 Sep 2017

Podcast listeners, check it out: Today, I’m starting a new podcast for biotech adventurers like you – executives, investors, scientists. It’s called The Long Run. Here’s the gist: Antarctic explorer Ernest Shackleton, if he were alive, would appreciate biotech. Today’s scientific entrepreneurs must be ready for the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return...